Skip Navigation


Rheumatology Advance Access originally published online on March 3, 2007
Rheumatology 2007 46(4):563-564; doi:10.1093/rheumatology/kel424
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
46/4/563    most recent
kel424v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Dörner, T.
Right arrow Articles by Burmester, G. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dörner, T.
Right arrow Articles by Burmester, G. R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

EDITORIALS

No B cells—no active RA? Advances in B cell depletion in RA—repeated therapy under conditions of clinical practice

T. Dörner and G. R. Burmester

Charite Universitätsmedizin and Deutsches Rheumaforschungszentrum, Berlin, Germany.

Correspondence to: Prof. Dr Thomas Dörner. E-mail: thomas.doerner@charite.de

The first 150 words of the full text of this article appear below.

Early observations in 1999 by Jo Edwards’ group at University College London, UK [1] provided evidence that using a B-cell depleting antibody licensed for non-Hodgkin lymphoma was able to significantly reduce signs and symptoms of RA with an acceptable safety profile during a single treatment course of induced B-cell depletion and subsequently led to clinical development of this drug based on large randomized clinical trials (proof of concept/IIa, DANCER, REFLEX) and finally to approval in the US, Switzerland and the EU for this indication. This is the first cell-directed therapy for the treatment of RA arriving in the clinics after studies of T-cell directed therapy using anti-CD4 antibodies opened this area more than 10 yrs ago [2]. Importantly, it offers alternative treatment options to severe RA patients inadequately responding to TNF blockers.

The breath-taking pace of this clinical development with inducing a clinical response for several . . . [Full Text of this Article]

Retreatment

Subsets of patients

Most frequently occurring side effects

Mechanism of action

Conclusion


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
J. C. W. Edwards, G. Cambridge, and M. J. Leandro
Repeated B-cell depletion in clinical practice
Rheumatology, September 1, 2007; 46(9): 1509 - 1509.
[Full Text] [PDF]